Comparison of dantrolene sodium with erythromycin estolate using primary cultures of rat hepatocytes.

Using primary cultures of parenchymal hepatocytes as a model system, the cytotoxic potential of dantrolene sodium (DS) was compared with that of erythromycin estolate (EE)--a known hepatotoxin. Parallel morphological and functional comparisons were made, following 4-, 8-, or 24-h exposures of hepatocyte cultures, using phase contrast microscopy and lactate dehydrogenase (LDH) leakage, respectively. Four-hour exposures of cultures to rather low concentrations of EE (i.e. 50 microM) resulted in cellular necrosis and significantly elevated LDH release. As the concentration of this hepatotoxin was increased, the changes were more pronounced. However, even 4- or 8-h exposures of cultures to a maximum of 100 microM DS did not affect LDH leakage or morphological integrity, although marginally detectable morphological changes did not occur at the highest concentration after 24-h. The value of using primary parenchymal hepatocyte cultures as a model system for the assessment of xenobiotic-induced hepatotoxicity was confirmed.

[1]  A. J. Gandolfi,et al.  Hepatotoxicological evaluation of dantrolene sodium. , 1984, Drug and chemical toxicology.

[2]  W. Inman,et al.  Erythromycin estolate and jaundice. , 1983, British medical journal.

[3]  J. Jalife,et al.  Dantrolene sodium: effects on isolated cardiac tissues. , 1983, Journal of molecular and cellular cardiology.

[4]  Arnold Th,et al.  Dantrolene sodium: urinary metabolites and hepatotoxicity. , 1983 .

[5]  H. Lüllmann,et al.  A comparison of the effect of dantrolene upon the contractile response of different heart muscles and of a skeletal muscle preparation. , 1982, Pharmacological Research Communications.

[6]  D. Conte Camerino,et al.  Effects of dantrolene sodium on the contractile properties of isolated guinea-pig pyeloureter. , 1982, Pharmacological research communications.

[7]  D. Acosta,et al.  Metabolic activation and cytotoxicity of cyclophosphamide in primary cultures of postnatal rat hepatocytes. , 1981, Biochemical pharmacology.

[8]  D. Acosta,et al.  Evaluation of the cytotoxicity of tricyclic antidepressants in primary cultures of rat hepatocytes. , 1981, Journal of toxicology and environmental health.

[9]  D. Acosta,et al.  Evaluation of cytotoxicity in cultured cells by enzyme leakage , 1980 .

[10]  Toshikazu Nakamura,et al.  BIOCHEMICAL FUNCTIONS OF ADULT RAT HEPATOCYTES IN PRIMARY CULTURE * , 1980, Annals of the New York Academy of Sciences.

[11]  M. Csuka,et al.  Erythromycin ethylsuccinate hepatotoxicity. , 1980, JAMA.

[12]  S. Roy,et al.  Interaction of dantrolene with the hepatic mixed function oxidase system. , 1980, Research communications in chemical pathology and pharmacology.

[13]  H. Zimmerman,et al.  Cytotoxic effects of erythromycin estolate and chlorpromazine on hepatocytes isolated from rats of varying ages: A brief note , 1980, Mechanisms of Ageing and Development.

[14]  C. Dujovne,et al.  Erythromycin estolate vs. erythromycin base, surface excess properties and surface scanning changes in isolated liver cell systems. , 1980, Pharmacology.

[15]  D. Pessayre,et al.  Hepatotoxicity of erythromycin derivatives. , 1979, British medical journal.

[16]  Hamrick Me,et al.  Dantrolene inhibition of the hepatic mixed function oxidase system. , 1979 .

[17]  E. Hodgson,et al.  Reviews in biochemical toxicology , 1979 .

[18]  H. Zimmerman,et al.  The effects of dantrolene sodium on excretory function in the isolated perfused rat liver. , 1978, Toxicology and applied pharmacology.

[19]  J. Lloyd-Still,et al.  Erythromycin estolate hepatotoxicity. , 1978, A M A Journal of Diseases of Children.

[20]  C. Dujovne Hepatotoxic and cellular uptake interactions among surface active components of erythromycin preparations. , 1978, Biochemical Pharmacology.

[21]  E. Kass,et al.  Hepatotoxicity of Erythromycin Estolate During Pregnancy , 1977, Antimicrobial Agents and Chemotherapy.

[22]  J. Boitnott,et al.  Dantrolene-associated hepatic injury. Incidence and character. , 1977, Gastroenterology.

[23]  A. Gildon,et al.  Erythromycin Estolate Induced Hepatotoxicity , 1977 .

[24]  H. Eichenwald,et al.  Erythromycin: a review of its uses in pediatric practice. , 1976, The Journal of pediatrics.

[25]  S. Huang,et al.  Jaundice due to erythromycin estolate. , 1975, Gastroenterology.

[26]  M. H. Dykes Evaluation of a muscle relaxant: dantrolene sodium (Dantrium). , 1975, JAMA.

[27]  J. Freston,et al.  Chemical structure of erythromycin and hepatotoxicity. , 1974, Annals of internal medicine.

[28]  Basmajian Jv,et al.  Dantrolene sodium: long-term effects in severe spasticity. , 1973 .

[29]  R. Herman,et al.  Treatment of spasticity with dantrolene sodium. , 1973, American Journal of Physical Medicine.

[30]  C. Dujovne,et al.  Toxicity of a hepatotoxic laxative preparation in tissue culture and excretion in bile in man , 1972, Clinical pharmacology and therapeutics.

[31]  L. Lasagna,et al.  Experimental bases for the different hepatotoxicity of erythromycin preparations in man. , 1972, The Journal of laboratory and clinical medicine.

[32]  H. Leffert,et al.  STUDIES ON PRIMARY CULTURES OF DIFFERENTIATED FETAL LIVER CELLS , 1972, The Journal of cell biology.

[33]  L. Lasagna,et al.  Toxicity of hepatotoxic drugs on mouse liver tissue culture. , 1970, Archives internationales de pharmacodynamie et de therapie.

[34]  P. Braun Hepatotoxicity of erythromycin. , 1969, The Journal of infectious diseases.

[35]  H. Fischer,et al.  MIMICRY OF ACUTE CHOLECYSTITIS BY ERYTHROMYCIN ESTOLATE REACTIONS. REPORT OF 2 CASES , 1964, The American journal of the medical sciences.

[36]  A. Brown Two Cases of Untoward Reaction after“Ilosone” , 1963, British medical journal.

[37]  M. M. Robinson HEPATIC DYSFUNCTION ASSOCIATED WITH TRIACETYLOLEANDOMYCIN AND PROPIONYL ERYTHROMYCIN ESTER LAURYL SULFATE , 1962, The American journal of the medical sciences.

[38]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[39]  L. Goodman,et al.  THE PHARMACOLOGICAL BASIS OF THERAPEUTICS , 1966 .